MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.74
+0.11
+1.27%
After Hours: 8.74 0 0.00% 16:35 05/17 EDT
OPEN
8.53
PREV CLOSE
8.63
HIGH
8.80
LOW
8.48
VOLUME
294.91K
TURNOVER
--
52 WEEK HIGH
15.42
52 WEEK LOW
7.63
MARKET CAP
663.45M
P/E (TTM)
-2.5229
1D
5D
1M
3M
1Y
5Y
SMMT, CLSD, ADBE and AVDL among after-hours movers
Gainers: [[SMMT]] +12.4%. [[CLSD]] +8.4%. [[RADI]] +7.8%. [[APLS]] +7.3%. [[OLED]] +3.9%.Losers: [[AVDL]] -3.0%. [[ADBE]] -2.8%. [[WISH]] -2.8%. [[GOSS]] -2.6%. [[BDTX]] -2.4%.
Seekingalpha · 3d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 5d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 6d ago
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial result...
Business Wire · 05/06 12:31
Gossamer Bio EPS misses by $0.01
Gossamer Bio (GOSS): Q1 GAAP EPS of -$0.78 misses by $0.01.Cash, cash equivalents and marketable securities of $453M.Press Release
Seekingalpha · 05/06 12:02
BRIEF-Gossamer Bio Announces Q1 Loss Per Share Of $0.78
reuters.com · 05/06 11:34
Gossamer Bio's chief scientific officer Luisa Salter-Cid to resign
Gossamer Bio (GOSS) announces that Luisa Salter-Cid, the company's Chief Scientific Officer, will resign effective April 30, 2021.The company's Senior Vice President, Research & Translational Biology, Laura Carter, will be promoted to the
Seekingalpha · 04/20 12:04
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Ci...
Business Wire · 04/20 11:50
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOSS. Analyze the recent business situations of Gossamer Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GOSS stock price target is 19.57 with a high estimate of 25.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 157
Institutional Holdings: 59.40M
% Owned: 78.26%
Shares Outstanding: 75.91M
TypeInstitutionsShares
Increased
48
6.32M
New
17
3.09M
Decreased
31
8.66M
Sold Out
22
3.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/President/Chief Executive Officer/Director
Faheem Hasnain
Non-Executive Chairman
faheem Hasnain
Chief Financial Officer
Bryan Giraudo
Executive Vice President/General Counsel
Christian Waage
Other
Jakob Dupont
Director
Russell J. Cox
Independent Director
Joshua Bilenker
Independent Director
Kristina Burow
Independent Director
Russell Cox
Independent Director
Thomas Daniel
Independent Director
Renee Gala
No Data
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.

Webull offers kinds of Gossamer Bio Inc stock information, including NASDAQ:GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.